|
|
|
Corporate Profile:
Optherion
| Summary: |
| Optherion is focused on developing diagnostics and therapeutics for early-stage age-related macular degeneration, dense deposit disease, membranoproliferative glomerulonephritis, atypical hemolytic uremic syndrome, and other chronic diseases involving the alternative complement cascade. |
| Address: |
The Maritime Center
11th Floor
555 Long Wharf Drive
New Haven, CT 06511 |
| Phone
#'s: |
| Main |
(203) 781-0072 |
| Human
Resources |
(203) 492-0282 |
| Investor
Relations |
not known |
| Fax
#'s: |
| Main |
(203) 492-0299 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| email: |
| Main |
not known |
| Human
Resources |
HR@optherion.com |
| Investor
Relations |
not known |
| Financial
information: |
| not known |
| Number
of employees: |
| not known |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
